Buprenorphine Treatment Centers in West Virginia

No age cap. Patients in their 60s, 70s, and 80s successfully receive buprenorphine in West Virginia. Older adults may need dose adjustments, additional ECG screening (for methadone), or monitoring for interactions with chronic-disease medications, but age alone is not a barrier.

Common extra charges include urine drug-screen add-ons ($10–$50), missed-appointment fees, and pharmacy dispensing fees for take-home methadone doses. Always ask for a written fee schedule before your first visit at any West Virginia provider.

Yes. Pregnancy-related West Virginia Medicaid (Mountain Health Trust) coverage includes MAT with no copays and priority access to West Virginia perinatal-MAT programs. Many West Virginia Medicaid (Mountain Health Trust) plans also extend coverage for 12 months postpartum to protect the mother–infant dyad.

Yes. TRICARE Prime and Select cover the full MAT benefit including buprenorphine. Active-duty service members may need command notification; retirees and dependents do not. Humana Military or Health Net Federal handles TRICARE claims depending on the West Virginia region.

West Virginia’s state behavioral-health authority licenses MAT facilities, and the Substance Abuse and Mental Health Services Administration (SAMHSA) certifies Opioid Treatment Programs. The Drug Enforcement Administration (DEA) regulates controlled-substance handling at every MAT site.

Early in treatment, visits are weekly — sometimes daily for methadone induction. After stabilization, buprenorphine patients typically visit monthly, and methadone patients may qualify for take-home doses reducing visits to bi-weekly or monthly. Naltrexone injections are monthly.

No. West Virginia employers have no right to require MAT disclosure. ADA protections and 42 CFR Part 2 confidentiality prevent providers from disclosing MAT status to employers. If you need FMLA for appointments, your HR can verify medical leave without knowing the diagnosis.

First doses are intentionally cautious — 5–10 mg of buprenorphine or 20–30 mg of methadone — to assess tolerance and avoid over-sedation. Your dose is titrated up over the first 1–2 weeks until cravings and withdrawal are controlled.

Routine liver-function tests are monitored at MAT intake and periodically thereafter. Buprenorphine and methadone are hepatically cleared; naltrexone carries a liver-toxicity warning in high doses. West Virginia clinicians adjust dosing or select alternatives for patients with pre-existing liver disease.

Yes. Methadone and buprenorphine are compatible with breastfeeding per CDC and AAP guidance; the small amounts in breast milk are protective against NOWS. Naltrexone in breastfeeding is less studied — discuss with your West Virginia OB and MAT provider together.

Patients prescribed buprenorphine or naltrexone in West Virginia can technically receive medication without counseling, but outcomes are significantly better with integrated counseling. Methadone patients at OTPs have counseling requirements per federal rule 42 CFR Part 8.

Buprenorphine and naltrexone prescriptions appear on pharmacy records like other prescriptions and are visible to dispensing pharmacies and authorized users of the PDMP. Methadone dispensed at an OTP is not reported to retail pharmacy systems.